MX2015013254A - Composiciones de agente activo retinoide particuladas, secas y finas y formulaciones topicas que incluyen las mismas. - Google Patents

Composiciones de agente activo retinoide particuladas, secas y finas y formulaciones topicas que incluyen las mismas.

Info

Publication number
MX2015013254A
MX2015013254A MX2015013254A MX2015013254A MX2015013254A MX 2015013254 A MX2015013254 A MX 2015013254A MX 2015013254 A MX2015013254 A MX 2015013254A MX 2015013254 A MX2015013254 A MX 2015013254A MX 2015013254 A MX2015013254 A MX 2015013254A
Authority
MX
Mexico
Prior art keywords
topical formulations
active agent
same
agent compositions
dry particulate
Prior art date
Application number
MX2015013254A
Other languages
English (en)
Other versions
MX366277B (es
Inventor
Xin Chen
Zahra Mansouri
Rodica-Tatiana Canelide
Original Assignee
Lab Skin Care Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015013254(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lab Skin Care Inc filed Critical Lab Skin Care Inc
Publication of MX2015013254A publication Critical patent/MX2015013254A/es
Publication of MX366277B publication Critical patent/MX366277B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan composiciones de retinoide particulado seco y fino adecuadas para usarse en formulaciones tópicas, así como los métodos para hacer las mismas; en las composiciones de retinoides particulado, el agente activo de retinoide está asociado con las partículas, es decir, a través de atrapamiento de las partículas en los poros y/o enlace jónico y/o enlace no covalente de las partículas a la superficie y/o holgadamente asociado con las partículas; también se proporcionan formulaciones tópicas que incluyen las composiciones de retinoide particulado seco de la invención, y métodos para usar las mismas.
MX2015013254A 2013-03-15 2014-03-14 Composiciones de agente activo retinoide particuladas, secas y finas y formulaciones topicas que incluyen las mismas. MX366277B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798758P 2013-03-15 2013-03-15
US201461938080P 2014-02-10 2014-02-10
PCT/US2014/029673 WO2014145034A1 (en) 2013-03-15 2014-03-14 Fine dry particulate retinoid active agent compositions and topical formulations including the same

Publications (2)

Publication Number Publication Date
MX2015013254A true MX2015013254A (es) 2016-04-15
MX366277B MX366277B (es) 2019-07-04

Family

ID=51528082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013254A MX366277B (es) 2013-03-15 2014-03-14 Composiciones de agente activo retinoide particuladas, secas y finas y formulaciones topicas que incluyen las mismas.

Country Status (16)

Country Link
US (5) US20140271879A1 (es)
EP (1) EP2968157B1 (es)
JP (1) JP2016514694A (es)
KR (1) KR20150131285A (es)
CN (2) CN105358135A (es)
AU (1) AU2014233420A1 (es)
BR (1) BR112015023117A2 (es)
CA (1) CA2906838A1 (es)
CL (1) CL2015002688A1 (es)
EA (1) EA201591826A1 (es)
ES (1) ES2975482T3 (es)
MX (1) MX366277B (es)
MY (1) MY183106A (es)
NZ (1) NZ713342A (es)
SG (1) SG11201507667SA (es)
WO (1) WO2014145034A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180089553A (ko) * 2008-09-23 2018-08-08 라보라토리 스킨 케어, 인크. 활성제 장입된 균일하고 강성이면서 구형의 나노다공성 인산칼슘 입자 및 그의 제조 방법과 그의 용도
ES2975482T3 (es) * 2013-03-15 2024-07-08 Laboratory Skin Care Inc Composiciones de partículas secas finas del agente activo retinoide y formulaciones tópicas que las incluyen
US10045925B2 (en) * 2014-11-03 2018-08-14 Stella & Dot Llc Skincare formulations and regimens
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
CN113181073B (zh) * 2021-04-30 2022-12-23 广州市科能化妆品科研有限公司 一种复合维生素乳液、祛皱精华霜及其制备方法
CN119654146A (zh) * 2022-08-31 2025-03-18 莱雅公司 用于护理角蛋白材料的组合物和包含它的敷膜
CN115820338A (zh) * 2023-02-22 2023-03-21 中国科学院昆明植物研究所 一种脱臭青刺果油的制备方法及其应用
CN118852023A (zh) * 2024-07-17 2024-10-29 南京工业大学 一种l-肌肽球形晶体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559149A (en) * 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
FR2717686B1 (fr) * 1994-03-22 1996-06-28 Fabre Pierre Cosmetique Composition dermo-cosmétologique et procédé de préparation.
US6096324A (en) * 1995-06-13 2000-08-01 Laboratory Skin Care Methods of delivering materials into the skin, and compositions used therein
US5851538A (en) * 1995-12-29 1998-12-22 Advanced Polymer Systems, Inc. Retinoid formulations in porous microspheres for reduced irritation and enhanced stability
FR2774907B1 (fr) * 1998-02-19 2000-05-12 Luc Dewandre Nouvelle formulation topique a base de retinaldehyde
US6358517B1 (en) * 1999-10-22 2002-03-19 Unilever Home & Personal Care Usa, Division Of Conopco Cosmetic compositions containing resveratrol and retinoids
DE10233740A1 (de) * 2002-07-24 2004-02-05 Basf Ag Retinoid-haltige Zubereitungen
US20040180091A1 (en) * 2003-03-13 2004-09-16 Chang-Yi Lin Carbonated hydroxyapatite-based microspherical composites for biomedical uses
EP1674093A4 (en) * 2003-10-15 2009-12-09 Nanoegg Res Lab Inc METHOD OF CHECKING THE PARTICLE SIZE OF RETINOLIC ACID NANOTEILS WITH A COATING OF POLYVALENT INORGANIC METAL SALT AND NANOTEHTES OBTAINED BY THE CONTROL PROCEDURE
US20100330014A1 (en) * 2008-01-30 2010-12-30 Tbc Group Co., Ltd. Composition for external application on skin, and skin-whitening cosmetic
KR20180089553A (ko) 2008-09-23 2018-08-08 라보라토리 스킨 케어, 인크. 활성제 장입된 균일하고 강성이면서 구형의 나노다공성 인산칼슘 입자 및 그의 제조 방법과 그의 용도
WO2010050980A1 (en) 2008-10-31 2010-05-06 Laboratory Skin Care, Inc. Topical formulations comprising hydroxyapatite particles for stimulation and maintenance of collagen fibers
KR101909711B1 (ko) * 2009-05-06 2018-12-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
WO2011060099A2 (en) * 2009-11-10 2011-05-19 Laboratory Skin Care, Inc. Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles, and methods of making and using the same
ES2975482T3 (es) * 2013-03-15 2024-07-08 Laboratory Skin Care Inc Composiciones de partículas secas finas del agente activo retinoide y formulaciones tópicas que las incluyen
WO2019068096A1 (en) * 2017-09-29 2019-04-04 Rodan & Fields, Llc COMPOSITIONS CONTAINING RETINALDEHYDE AND METHODS OF USE

Also Published As

Publication number Publication date
NZ713342A (en) 2020-12-18
WO2014145034A1 (en) 2014-09-18
CN105358135A (zh) 2016-02-24
ES2975482T3 (es) 2024-07-08
EP2968157A4 (en) 2016-12-14
US20180028469A1 (en) 2018-02-01
CL2015002688A1 (es) 2016-04-08
JP2016514694A (ja) 2016-05-23
MY183106A (en) 2021-02-15
SG11201507667SA (en) 2015-10-29
US20160317469A1 (en) 2016-11-03
EP2968157A1 (en) 2016-01-20
CN112263549A (zh) 2021-01-26
US20210259991A1 (en) 2021-08-26
KR20150131285A (ko) 2015-11-24
AU2014233420A8 (en) 2015-11-26
MX366277B (es) 2019-07-04
BR112015023117A2 (pt) 2017-07-18
EP2968157B1 (en) 2023-11-08
US20200222336A1 (en) 2020-07-16
US20140271879A1 (en) 2014-09-18
EA201591826A1 (ru) 2016-01-29
AU2014233420A1 (en) 2015-11-12
CA2906838A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
MX2015013254A (es) Composiciones de agente activo retinoide particuladas, secas y finas y formulaciones topicas que incluyen las mismas.
LT3215133T (lt) Būdai ir kompozicijos, susiję su žemos hlp paviršinio aktyvumo medžiagų naudojimu sintetinių nanonešiklių, apimančių rapalogą, gamyboje
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015002860A1 (es) Antagonistas de la alfa-v-beta-6 integrina
PL3488485T3 (pl) Sposób suszenia zespołów elektrod
PL3516315T3 (pl) Sposób suszenia zespołów elektrod
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2015003140A (es) Formulaciones de enzalutamida.
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CL2015002473A1 (es) Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhibidores de la phd.
CL2015002030A1 (es) Dihidropirimidinomas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica
CL2014003462A1 (es) Uso de compuestos aminotriazolopiridinas sustituidos, en el tratamiento de afecciones inflamatorias, autoinmunitarias, proliferativas, alergias, rechazo de trasplantes, entre otras; composicion farmaceutica que los comprende; combinacion farmaceutica.
UY35281A (es) Composiciones que incluyen agentes para conferir carácter hidrofóbico y estabilizantes y métodos para elaborar y usar los mismos
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
SV2016005301A (es) Nuevos compuestos macrocíclicos
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
CL2015002470A1 (es) Composición para formar una estructura porosa absorbente
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
BR112014031706A8 (pt) Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
UY34761A (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos.
MX374618B (es) Ésteres sulfatados de ácidos oligohidroxicarboxílicos, y uso de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration